Nikko Asset Management Americas Inc. Acquires 236,620 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Nikko Asset Management Americas Inc. grew its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 42.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 789,222 shares of the company's stock after purchasing an additional 236,620 shares during the quarter. Nikko Asset Management Americas Inc. owned approximately 1.04% of Nurix Therapeutics worth $14,869,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of NRIX. Amalgamated Bank grew its stake in shares of Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company's stock worth $49,000 after acquiring an additional 511 shares in the last quarter. US Bancorp DE grew its position in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock worth $27,000 after purchasing an additional 842 shares in the last quarter. Quest Partners LLC grew its position in Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company's stock worth $168,000 after purchasing an additional 1,312 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its stake in Nurix Therapeutics by 8.4% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 30,024 shares of the company's stock valued at $675,000 after buying an additional 2,329 shares during the last quarter. Finally, Quarry LP lifted its position in shares of Nurix Therapeutics by 3,746.2% during the 3rd quarter. Quarry LP now owns 2,500 shares of the company's stock worth $56,000 after buying an additional 2,435 shares in the last quarter.

Remove Ads

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock traded down $0.88 during midday trading on Friday, reaching $12.99. 2,288,289 shares of the stock were exchanged, compared to its average volume of 868,315. The company's fifty day moving average is $17.10 and its 200-day moving average is $20.88. Nurix Therapeutics, Inc. has a 52 week low of $11.90 and a 52 week high of $29.56. The firm has a market cap of $985.77 million, a PE ratio of -4.49 and a beta of 2.18.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the sale, the insider now directly owns 55,937 shares of the company's stock, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Houte Hans Van sold 5,825 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares of the company's stock, valued at approximately $488,660.76. This represents a 14.73 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,326 shares of company stock worth $213,449. 7.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently commented on NRIX shares. Stephens reiterated an "overweight" rating and set a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, January 21st. JPMorgan Chase & Co. lowered their target price on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Leerink Partners started coverage on shares of Nurix Therapeutics in a research report on Monday. They set a "market perform" rating and a $16.00 price target for the company. Morgan Stanley lifted their price objective on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a research report on Monday, February 3rd. Finally, Royal Bank of Canada increased their target price on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, Nurix Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $30.88.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.